About
Commitment to Innovation
Next-Generation CDK Therapies for Cancers Beyond CDK4/6
Restoring durable cell-cycle and transcriptional control in RB-independent, p53-mutant, KRAS-mutant, and treatment-resistant malignancies
Next-Generation CDK Therapies for Resistant Cancers
SPV Therapeutics, Inc. is developing next-generation, precision cyclin-dependent kinase (CDK)–targeted therapies intended to address cell-cycle and transcriptional dysregulation in cancers where clinical benefit from first-generation CDK4/6 inhibitors may be limited by the emergence of resistance.
Grounded in well-established CDK biology, SPV’s approach centers on a single-enantiomer (enantiopure) precision strategy based on balanced, multi-node CDK targeting, including CDK4/6 and CDK9, to interrogate tumor contexts associated with therapeutic resistance—such as RB-independent, p53-mutated, and KRAS-driven malignancies—where selective CDK4/6 inhibition alone may be insufficient.
Headquartered in Research Triangle Park, a globally recognized life-science and innovation hub, SPV operates at the interface of cancer biology, medicinal chemistry, and translational science, with a focus on advancing differentiated therapeutic strategies for hard-to-treat cancers, including triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), and pancreatic ductal adenocarcinoma (PDAC).